Selected research
Industry Research
9-valent Human Papillomavirus Vaccine Industry Research Report 2026
Market perspective
The global 9-valent Human Papillomavirus Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for 9-valent Human Papillomavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for 9-valent Human Papillomavirus Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for 9-valent Human Papillomavirus Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of 9-valent Human Papillomavirus Vaccine include Zhifei Biological Products, Walvax Biotechnology, Wantai Biological Pharmacy, GSK, Beijing Health Guard Biotechnology and Merck Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global 9-valent Human Papillomavirus Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
9-valent Human Papillomavirus Vaccine Market by Company
Zhifei Biological Products
Walvax Biotechnology
Wantai Biological Pharmacy
GSK
Beijing Health Guard Biotechnology
Merck Group
9-valent Human Papillomavirus Vaccine Segment by Type
HPV11
HPV16
HPV18
HPV6
Others
9-valent Human Papillomavirus Vaccine Segment by Application
Health Center
Epidemic Prevention Station
Hospital
Others
9-valent Human Papillomavirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global 9-valent Human Papillomavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of 9-valent Human Papillomavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of 9-valent Human Papillomavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of 9-valent Human Papillomavirus Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of 9-valent Human Papillomavirus Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of 9-valent Human Papillomavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- HPV11
- HPV16
- HPV18
- HPV6
- Others
Applications
- Health Center
- Epidemic Prevention Station
- Hospital
- Others
Companies covered
- Zhifei Biological Products
- Walvax Biotechnology
- Wantai Biological Pharmacy
- GSK
- Beijing Health Guard Biotechnology
- Merck Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global 9-valent Human Papillomavirus Vaccine Market Size (2021-2032)
- 2.2.2 Global 9-valent Human Papillomavirus Vaccine Sales (2021-2032)
- 2.2.3 Global 9-valent Human Papillomavirus Vaccine Market Average Price (2021-2032)
- 2.3 9-valent Human Papillomavirus Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 HPV11
- 2.3.3 HPV16
- 2.3.4 HPV18
- 2.3.5 HPV6
- 2.3.6 Others
- 2.4 9-valent Human Papillomavirus Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Health Center
- 2.4.3 Epidemic Prevention Station
- 2.4.4 Hospital
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global 9-valent Human Papillomavirus Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global 9-valent Human Papillomavirus Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global 9-valent Human Papillomavirus Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global 9-valent Human Papillomavirus Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global 9-valent Human Papillomavirus Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of 9-valent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of 9-valent Human Papillomavirus Vaccine, Product Type & Application
- 3.8 Global Manufacturers of 9-valent Human Papillomavirus Vaccine, Established Date
- 3.9 Global 9-valent Human Papillomavirus Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhifei Biological Products
- 4.1.1 Zhifei Biological Products Company Information
- 4.1.2 Zhifei Biological Products Business Overview
- 4.1.3 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhifei Biological Products 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.1.5 Zhifei Biological Products Recent Developments
- 4.2 Walvax Biotechnology
- 4.2.1 Walvax Biotechnology Company Information
- 4.2.2 Walvax Biotechnology Business Overview
- 4.2.3 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Walvax Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.2.5 Walvax Biotechnology Recent Developments
- 4.3 Wantai Biological Pharmacy
- 4.3.1 Wantai Biological Pharmacy Company Information
- 4.3.2 Wantai Biological Pharmacy Business Overview
- 4.3.3 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Wantai Biological Pharmacy 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.3.5 Wantai Biological Pharmacy Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Beijing Health Guard Biotechnology
- 4.5.1 Beijing Health Guard Biotechnology Company Information
- 4.5.2 Beijing Health Guard Biotechnology Business Overview
- 4.5.3 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Beijing Health Guard Biotechnology 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.5.5 Beijing Health Guard Biotechnology Recent Developments
- 4.6 Merck Group
- 4.6.1 Merck Group Company Information
- 4.6.2 Merck Group Business Overview
- 4.6.3 Merck Group 9-valent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Merck Group 9-valent Human Papillomavirus Vaccine Product Portfolio
- 4.6.5 Merck Group Recent Developments
5 Global 9-valent Human Papillomavirus Vaccine Market Scenario by Region
- 5.1 Global 9-valent Human Papillomavirus Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2021-2032
- 5.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2021-2026
- 5.2.2 Global 9-valent Human Papillomavirus Vaccine Sales by Region: 2027-2032
- 5.3 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Region: 2027-2032
- 5.4 North America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
- 5.4.1 North America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
- 5.4.3 North America 9-valent Human Papillomavirus Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
- 5.5.1 Europe 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe 9-valent Human Papillomavirus Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific 9-valent Human Papillomavirus Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
- 5.7.1 South America 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
- 5.7.3 South America 9-valent Human Papillomavirus Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa 9-valent Human Papillomavirus Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa 9-valent Human Papillomavirus Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa 9-valent Human Papillomavirus Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2032)
- 6.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global 9-valent Human Papillomavirus Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2032)
- 7.1.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global 9-valent Human Papillomavirus Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global 9-valent Human Papillomavirus Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global 9-valent Human Papillomavirus Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global 9-valent Human Papillomavirus Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global 9-valent Human Papillomavirus Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 9-valent Human Papillomavirus Vaccine Value Chain Analysis
- 8.1.1 9-valent Human Papillomavirus Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 9-valent Human Papillomavirus Vaccine Production Mode & Process
- 8.2 9-valent Human Papillomavirus Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 9-valent Human Papillomavirus Vaccine Distributors
- 8.2.3 9-valent Human Papillomavirus Vaccine Customers
9 Global 9-valent Human Papillomavirus Vaccine Analyzing Market Dynamics
- 9.1 9-valent Human Papillomavirus Vaccine Industry Trends
- 9.2 9-valent Human Papillomavirus Vaccine Industry Drivers
- 9.3 9-valent Human Papillomavirus Vaccine Industry Opportunities and Challenges
- 9.4 9-valent Human Papillomavirus Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst